Kedrion S.p.A.

25 articles about Kedrion S.p.A.

• Kedrion Announces an Eight-Year Extension of the Distribution Agreement With Kamada in the US for KEDRAB®

  12/7/2023

  Kedrion Biopharma announces the execution of a binding memorandum of understanding with Kamada Ltd., an Israeli commercial stage global biopharmaceutical company and leader in the specialty plasma-derived field, for the amendment and the 8-year extension of the KEDRAB® US distribution agreement between the two companies.

• Kedrion Biopharma Marks Fourth Annual Hereditary Factor 10 Deficiency Day on October 10

  10/10/2023

  Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, is proud to recognize the fourth Hereditary Factor X Deficiency Awareness Day on October 10, 2023.

• Kedrion Biopharma Announces Support for the Immune Deficiency Foundation Research Grant Program for Second Consecutive Year

  7/25/2023

  Kedrion Biopharma, an international biopharmaceutical company specializing in the production and distribution of plasma-derived therapeutic products used in treating rare and serious diseases recently announced its support of the Immune Deficiency Foundation Research Grant Program for the second year in a row.

• Liminal BioSciences Announces Closing of Sale of Remaining Plasma-Derived Therapeutics Business

  10/15/2021

  Liminal BioSciences Inc., announced that it has closed on the sale of the remainder of the Company's plasma-derived therapeutics business under the terms of the previously-announced Share Purchase Agreement entered into by the Company and Kedrion S.p.A..

• Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility

  7/9/2021

  LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, announced that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. .

• Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

  6/2/2021

  World Health Organization Estimates up to 40 Percent of People Exposed to a Suspected Rabid Animal are Children Under 15 Years of Age

• Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion

  5/21/2021

  Liminal BioSciences Inc. (Nasdaq: LMNL), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its 2 plasma collection centers, Prometic Plasma Resources Inc. and Prometic Plasma Resources

• Liminal BioSciences Enters into Agreement with Kedrion to Divest Its Plasma Collection and Plasma-Derived Therapeutics Business

  5/17/2021

  Kedrion to acquire, for a total of USD 17M , 2 plasma collection centers and an option to acquire the remaining plasma-derived therapeutic business for USD 5M Liminal to receive up to 70% of net proceeds from sale of Priority Review Voucher for which it is potentially eligible with possible FDA approval for Ryplazim ®

• Kamada and Kedrion Biopharma Announce Results of First and Only U.S. Post-Marketing Pediatric Trial of a Human Rabies Immune Globulin (HRIG); The Study Met Its Primary Objective

  8/19/2020

  The Study of KEDRAB®(Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S.

• 

  Biopharma Update on the Novel Coronavirus: April 27

  4/27/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
• 

  Biopharma Update on the Novel Coronavirus: April 8

  4/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 8, 2020.

• Partnership Between FSI and Kedrion to Continue the Growth and Development Plan of the Company

  10/16/2019

  Sestant Internazionale S.p.A., Sestant S.p.A. and FSI Investimenti, shareholders of Kedrion S.p.A., have signed an agreement with FSI, under the terms of which the latter will acquire a minority stake from Sestant Internazionale S.p.A. and subscribe a capital increase to become a shareholder of Kedrion with 19.59%..

• Kedrion And Kamada Receive FDA Approval Of KEDRAB For Post-Exposure Prophylaxis Against Rabies Infection

  8/25/2017

• Kedrion And Kamada Ltd. Announce FDA Acceptance Of BLA Submission For Human Rabies Immunoglobulin As A Post-Exposure Treatment

  11/7/2016

• Kamada Ltd. And Kedrion Seek FDA Approval Of Human Rabies Immunoglobulin As A Post-Exposure Treatment

  9/1/2016

• Kedrion Receives FDA Approval To Package Koate Double Viral Inactivation (DVI) Antihemophilic Factor (Human) With Mix2Vial Needle-Free Transfer Device

  3/28/2016

• Kedrion S.p.A. Continues Global Expansion With Dedication Ceremony At United States Facility

  5/18/2015

• Entegrion Announces Kedrion S.p.A. Collaboration to Develop Blood Product Technology

  3/19/2013

• Kedrion S.p.A. Launches US Subsidiary with Acquisition of Koate(R)-DVI

  6/13/2011

• ProMetic Life Sciences Inc. Announces Signature of Definitive License Agreement With Kedrion S.p.A. for Two Hyperimmune Products

  2/27/2008